PIONEERING A NEW CLASS OF THERAPEUTIC ANTIBODIES Our mission is to improve the treatment of cancer by creating and developing novel IgM and IgA antibodies. IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors August, 2018 – Dr. Hambleton Brings More Than 25 Years of Industry and Academic Experience – MOUNTAIN... Read More... IGM Biosciences Appoints Daniel S. Chen, M.D., Ph.D., as Chief Medical Officer; Names William Strohl, Ph.D., to Board of Directors August, 2018 – Dr. Daniel Chen, Former Global Head of Cancer Immunotherapy Development at Genentech/Roche and Noted... Read More... Multimeric Anti-DR5 IgM antibody displays potent cytotoxicity in vitro and promotes tumor regression in vivo April, 2017 Read More... High Avidity Anti-CD20 IgM Antibody for Enhanced Complement-Dependent Cell Killing of Low CD20 Expressing Tumor Cells April, 2016 Read More... IGM-55.5, a novel monoclonal human recombinant IgM antibody with potent activity against B cell leukemia and lymphoma April, 2014 Read More...
